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Abstract
Background: Subsets of cells with stem-like properties have been previously isolated from human epithelial cancers 
and their resistance to apoptosis-inducing stimuli has been related to carcinoma recurrence and treatment failure. The 
aim of this study was to investigate the mechanisms of resistance to apoptosis-inducing agents of cells with stem-like 
properties in both normal and malignant human epithelia.
Methods: Cells isolated from fresh human head and neck carcinomas (n = 11), cell lines derived from head and neck, 
prostate and breast human carcinomas (n = 7), and from normal human oral mucosa (n = 5), were exposed to various 
apoptosis-inducing stimuli (UV, Tumour Necrosis Factor, Cisplatin, Etoposide, and Neocarzinostatin). Flow cytometry for 
CD44 and epithelial-specific antigen (ESA) expression, colony morphology, tumour sphere formation and rapid 
adherence assays were used to identify the subset of cells with stem-like properties. Apoptosis, cell cycle and 
expression of various cell cycle checkpoint proteins were assessed (Western Blot, qPCR). The role of G2-checkpoint 
regulators Chk1 and Chk2 was investigated by use of debromohymenialdisine (DBH) and siRNA.
Results: In both cancer biopsies and carcinoma cell lines a subset of CD44high cells showed increased clonogenicity, a 
significantly lower rate of apoptosis, and a significantly higher proportion of cells in the G2-phase of the cell cycle. An 
inverse correlation between the percentage of cells in G2-phase and the rate of apoptosis was found. Pulse-chase with 
iododeoxyuridine (IdU) demonstrated that CD44high carcinoma cells spent longer time in G2, even in un-treated 
controls. These cells expressed higher levels of G2 checkpoint proteins, and their release from G2 with BDH or Chk1 
siRNA increased their rate of apoptosis. Low passage cultures of normal keratinocytes were also found to contain a 
subset of CD44high cells showing increased clonogenicity, and a similar pattern of G2-block associated with apoptotic 
resistance.
Conclusions: These data indicate that both normal and malignant human epithelial cells with stem-like properties 
show greater resistance to apoptosis associated with extended G2 cell cycle phase, and that this property is not a 
consequence of neoplastic transformation. Targeting G2 checkpoint proteins releases these cells from the G2-block 
and makes them more prone to apoptosis, implying an opportunity for improved therapeutic approaches.
Background
About one in five US and European deaths is caused by
cancer and about four out of five cancer deaths result
from cancers of epithelial origin [1-3]. Head and neck
squamous cell carcinoma (HNSCC) is the sixth most
common malignancy worldwide [4] and, as for other can-
cers, it is commonly associated with death from tumour
recurrence following initial therapy [5]. There is growing
awareness that such therapeutic failure may, among other
factors, be related to patterns of cellular heterogeneity
within tumours [6,7], and the idea that the growth of can-
cers is associated with a sub-population of cells with
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Page 2 of 16stem-like properties, the so called "cancer stem cells" has
been discussed for over a century [8]. The continuing
growth of malignancies points to the presence of at least
some cells with extended self-renewal potential and the
usual tumour mimicry of the tissue of origin indicates
attempted differentiation of some malignant cells [9].
Thus some tumour cells have the ability for indefinite
self-renewal while generating cells that enter differentia-
tion pathways, properties that correspond to the essential
basic properties of normal adult somatic stem cells [10].
Further support for this idea has lately been generated by
the ability to isolate and assess the tumour-initiating
properties of various cell fractions isolated by fluores-
cence-activated cell sorting (FACS) based on certain cell
surface markers such as CD34, CD44 or CD133 [7]. Fol-
lowing the early identification of cells with stem-like
properties in haematopoietic malignancies [11,12], pro-
spective identification and isolation of such cell subpopu-
lations has been achieved for an expanding range of solid
human tumours, including head and neck, breast and
prostate cancers [13-18].
Presence of subpopulations of cells with stem-like
properties has also been demonstrated in cell lines
derived from various cancers [19-23]. Such cells could be
identified in vitro not only by high cell surface expression
of various markers such as CD44 [20-22], but also by
additional, robust methods such as rapid adherence to
culture dishes [19] or colony morphology (holoclones,
containing small tightly-packed cells vs. meroclones or
paraclones, irregular colonies containing large cells)
[21,23]. It has recently been shown that their increased in
vitro clonogenicity correlated well with in vivo tumour
initiating abilities [22,23].
The primary therapeutic importance of cancer cells
with stem-like properties relates to their abilities to resist
therapeutic killing in response to chemo- and radio-ther-
apies [7,12,24,25]. Differences in apoptotic sensitivity
between the cells with stem-like properties and the rest of
the tumour cell population might have therapeutic conse-
quences, the death of mainly the non-stem-like fraction
possibly explaining the frequently observed clinical
response of early loss of tumour mass followed by later
recurrence [10,24,26]. However, although the survival of
cells with stem-like properties in some carcinomas has
been attributed to an enhanced ability for drug removal,
reduced DNA damage, or enhanced DNA repair
[24,27,28], the mechanisms behind their differential resis-
tance to apoptosis are not yet clear, nor are they investi-
gated in a broad range of carcinomas or in normal human
epithelium. There is a need for more information about
the general applicability of such phenomena to carcinoma
recurrence, and especially of HNSCC that is character-
ised by particularly high recurrence rates [29]. Investigat-
ing cell populations derived from a quite broad range of
carcinomas (head and neck, breast and prostate), and
from both fresh tumours and cell lines, the present study
shows that the low apoptotic rates consistently observed
in the subset of carcinoma cells with stem-like properties
are associated with unique cell cycle features that can be
therapeutically targeted. Of note is the observation that
this seems to be a constitutive trait of cells with stem-cell
properties in human adult epithelium and not acquired
during progression to malignancy.
Methods
Cell isolation from fresh biopsies of normal and malignant 
human oral mucosa
Tissue was collected from biopsies of normal human oral
mucosa (n = 5) and HNSCC tumours (n = 11) with writ-
ten informed patient consent and ethical approval
granted by the NE London & The City Ethics Committee.
Cultures of normal oral keratinocytes (NOK) were grown
as previously described [21]. Tumour tissue was minced
into pieces of approximately 1 mm3 and incubated for 20
min at 37°C in PBS containing 2.5 mg/ml collagenase I,
0.25% trypsin, and 0.01 mg/ml DNase (all from Sigma,
Dorset, UK). Cells for FACS analysis were used either
alive or after fixation in ice-cold 70% ethanol.
Cell culture
Cell lines derived from HNSCC (CA1, H357, 5PT, UK1,
CaLH3), breast (MCF7) and prostate (DU145) carcino-
mas were grown as previously described [19,21]. Cells
were plated at clonal density (2000 cells/ml) and individ-
ual colonies arising from single cells examined after 5-10
days for differences in morphology and staining for
CD44. For comparison of rates of proliferation, H357
cells plated at clonal density were labelled in the S phase
of the cell cycle by addition of 5-bromo-2-deoxyuridine
(BrdU, Sigma) to culture media to a final concentration of
50 μg/ml for 2 hours. Colonies developed from plated
cells were then fixed in 70% ethanol, and stained with an
antibody recognizing BrdU adducts (BD Biosciences,
Oxford, UK, Cat# 347583) as previously described [19].
For assays of ability to grow as "tumour spheres" in sus-
pension, CA1, CaLH3, H357 and MCF7 cells were grown
at clonal density for 4-5 days, removed from the dish by
trypsinisation, and sorted to obtain populations of
CD44high and CD44low cells. For MCF7 and H357 cell
lines, the sorted CD44highand CD44low cell subpopula-
tions were then resuspended in conditioned medium
with 0.4% low melting point agarose (Sigma) to a cell den-
sity of 2000 cells per ml. Cells were plated in triplicate 6
well plates pre-coated with a layer of 1% agarose and left
to grow for 2-3 weeks. To quantify sphere formation, 10
random fields of view were taken for each well and the
average number of spheres per field calculated. For CA1
and CaLH3 cell lines, the sorted CD44high and CD44low
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adherent 48-well plates and left to grow for 3 weeks to
grow for sphere formation. Three plates were quantified
for each cell line and each cell sub-population, and the
data is presented as % of the wells that contained spheres.
Induction and inhibition of apoptosis
CA1, H357, 5PT, UK1, CaLH3, MCF7, DU145 and NOK
cells, were plated at clonal density and after 7-10 days
apoptosis was induced by exposure to doses of UVB from
1 to 40 mj/cm2, to Cisplatin (50-1000 μM), to neocar-
zinostatin (NCZ) (10-100 ng/ml), to tumour necrosis fac-
tor (TNF, 10 ng/ml), or to etoposide (10-750 μM) (all
from Sigma) for 24 or 48 h. Unsorted cells of the CA1,
H357 and 5PT cell lines growing in situ at clonal density
were examined by phase contrast microscopy and were
also stained for cleaved Caspase 3 and Annexin V as
markers of apoptosis (see below). To assess effects of
Chk1 and Chk2 inhibition, debromohymenialdisine
(DBH, Axxora, Nottingham, UK) was added to the
growth media of the unsorted cells of the Ca1, 5PT,
CaLH2 and CaLH3 cell lines grown at clonal density to a
final concentration of 8 micromol/ml and cells analysed
18 hours later. Chk1 and Chk2 were also individually
down-regulated by transfection with either Chk1, Chk2
or non-targeting siRNAs (ON-TARGETplus SMART
pool siRNA, Dharmacon, Inc. Chicago, IL) in unsorted
cells of the CA1 and 5PT cell lines with cells stained and
assayed 48 h after transfection.
Recovery after apoptosis-inducing treatment
Sorted cells of the CA1 cell line (CD44high and
CD44lowsubpopulations) were plated at the same density,
exposed to UV (10 mj) and NCZ (20 ng/ml), left 4 days to
recover and then the number of floating (dead) cells was
counted. In another experiment, sorted cells of the CA1
cell line (CD44high and CD44low subpopulations) were
plated at similar density, exposed to apoptosis-inducing
drugs for 48 hours, and then trypsinized and plated again
at clonal density. The number of colonies formed was
counted in 5 different microscopic fields.
Immunocytochemistry
Unsorted cultured cells of the CA1, H357, 5PT, CaLH2,
CaLH3, MCF7, and DU145 cell lines were fixed in 4% for-
malin and immunostained as previously described [21].
Primary antibodies were anti-CD44 (1:100, BD Biosci-
ences, Oxford, UK) and anti-cleaved-Caspase-3 (1:250,
Promega, Southampton, UK). For Annexin V staining,
unsorted cells of the Ca1, H357 and NOK cell lines were
grown on culture dishes, washed with Annexin V binding
buffer (BD Biosciences) with 1% FBS, incubated for 10
min at 37°C with 10 μl FITC-Annexin V (BD Biosciences)
per mL in the same buffer, washed, fixed in 4% paraform-
aldehide, and mounted in VectaShield-DAPI (Vector lab-
oratories Inc, Burlingame, CA).
FACS analysis
For assessment of apoptotic sensitivities of CD44low and
CD44highcell fractions, cells isolated from fresh HNSCC
samples were quadruple stained with anti-epithelial-spe-
cific-antigen antibody (anti-ESA-APC), anti-CD44 anti-
body (anti-CD44-PE), AnnexinV-FITC, and DAPI. This
allowed distinction of tumour cells from stromal cells,
identification of CD44high and CD44low cells, and their
further classification into early (AnnexinV+ DAPI-) and
late (AnnexinV+ DAPI+) apoptotic fractions. IgG2ak-PE
was used as isotype control. For cell cycle analysis, the
cells isolated from fresh HNSCC were fixed and triple
stained with anti-ESA-APC antibody, anti-CD44-PE anti-
body, and PI. Typically, the 3-5% of cells with the highest
CD44 expression was designated as CD44high cell subset
and the remainder of the population was designated as
CD44low cell subset. Cell populations from CA1, H357,
5PT, UK1, CaLH3, MCF7, DU145 and NOK cell lines
were triple stained with anti-CD44-PE, AnnexinV-FITC,
and DAPI for assessment of apoptosis, or double stained
with anti-CD44-FITC and PI for cell cycle assays. To
assess apoptosis by loss of mitochondrial membrane
potential, a DilC1(5) assay (MitoProbe™ Invitrogen, Scot-
land) was used together with CD44 in a double staining
procedure according to manufacturers instructions for
CA1, H357 and MCF7 cell lines. To confirm the presence
of a G2 block, CaLH3 and H357 cells exposed to various
apoptotic-inducing agents were also stained with DAPI,
anti-CD44 antibody and anti-Cyclin B1 antibody (H-433,
Sc-752, Santa Cruz, Wiltshire, UK).
IdU pulse chase
To assess cell progression from G2 into G1, unsorted cells
of the CaLH3 and H357 cell lines were pulsed with 10 μM
2-Deoxy-5-Iodouridine (IdU) for 20 mins before washing
3 times in PBS and adding fresh medium. Immediately
and at 3, 5, 7, and 9 hours, cells were detaching from the
flask with Accutase, washed and pelleted, and fixed in ice
cold 70% ethanol. Cells were then co-stained with anti-
CD44-PE and FITC-conjugated antibody recognizing
IdU adducts (BD Pharmingen, Cat# 347583), and pro-
cessed for FACS analysis. Unless otherwise stated, all
FACS reagents were from BD Biosciences (Oxford, UK)
and cells were examined using Becton Dickenson LSRII
equipment and analysed with FACS Diva software.
Western blotting
Sorted CD44high and CD44low cells of the CA1 and H357
cell lines, or rapid adherent and late adhering cells of the
CA1 and CaLH3 cell lines [15] were isolated after treat-
ment with apoptosis-inducing agents and lysed using
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1%NP40) containing 1% protease inhibitor (Roche Diag-
nostics, Lewes, UK) and 1% phosphatase inhibitor
(Sigma). Protein content was determined using Bio-Rad
protein assay (Bio-Rad Laboratories, Hercules, CA, USA).
Ten μg total cell protein was mixed with SDS-PAGE buf-
fer and resolved using 4-12% NuPAGE b/Bis Tris Gels
(Invitrogen, Renfrew, UK). Proteins were transferred to
polyvinylfluoride (PVDF) membranes (Hybond-C Extra,
Amersham Pharmacia Biotech, Little Chalfont, UK). Pri-
mary antibodies were diluted 1:500 for anti-Chk1 pS317
(Bethyl Lab, TX, USA), 1 μg/ml anti-Chk2 pT26 (Abcam,
Cambridge, UK), 1:1000 anti-β-actin (Abcam), and
1:10,000 anti-GAPDH (Abcam).
Laser capture, RNA isolation and Q-PCR
Colonies of unsorted cells with holo- or para-clone mor-
phologies were laser micro-dissected from the CA1, UK1,
and 5PT cell lines, and CD44high and CD44low expressing
cells were FACS sorted from primary cultures of human
normal oral keratinocytes (NOK). Total RNA was
extracted using CellsDirect One-Step qRT-PCR kit, and
cDNA generated using SuperScript III first-strand syn-
thesis supermix for qRT-PCR (both from Invitrogen). Q-
PCR used a Brilliant SYBR Green kit (Stratagene, La Jolla,
CA, USA) and MX3005P apparatus with between 50 and
100 ng of cDNA probed using the following primers:
Wee1 - forward: gct ctg tta aac tcc ggg gta, reverse: gac
act gtc ctg agg aat gaa g; Myt1 - forward: caa ccg agg ctg
tcg aga aa, reverse: ctg tcc aca cca tag ccc t; GAPDH for-
ward: gtg aac cat gag aag tat gac aac, reverse: cat gag tcc
ttc cac gat acc.
Statistical analysis
Numerical data are shown as mean ± SD and are based
on a minimum of 3 repeats for each independent biologi-
cal sample (fresh tissue or cell line). Data was analysed
using SPSS version 15 statistical program (SPSS Inc. Chi-
cago, IL, USA), Students t-tests, and analysis of variance
(general linear model) with post-hoc tests (Bonferroni
multiple comparisons).
Results
CD44 expression correlates with in vitro colony 
morphology, clonogenicity and predicts the ability to grow 
in suspension as "tumour spheres"
Each of the seven human carcinoma cell lines investi-
gated in this study (CA1, H357, 5PT, CaLH2, CaLH3,
MCF7, and DU145) developed colonies with morpholo-
gies that corresponded, as previously described, to holo-
clone, meroclone and paraclone colonies (Fig. 1A, 1D).
Holoclone colonies showed strong expression of CD44
(Fig. 1B, 1E). When examined by FACS after removal
from culture dishes, the cell populations showed various
gradients of cell staining for CD44, with distinct sub-pop-
ulations of CD44high cells found in some cell lines (Fig.
1F). A similar pattern could be observed when analysing
carcinoma cells isolated from fresh biopsies of HNSCC
(Fig. 1G and 1H). Normal oral keratinocytes showed dif-
ferential levels of staining for CD44, although they did
not show discrete sub-populations of CD44high cells as
seen for some malignant cells (Fig. 1I). Sorting cells for
high or low levels of expression of CD44 showed, as pre-
viously indicated for carcinoma-derived cells [21], that
the CD44high cell fractions are more clonogenic when
plated in standard culture conditions and form a greater
proportion of colonies with holoclone morphologies for
both malignant and normal keratinocytes (Fig. 1J, 1K
and1L, respectively). Plating the CD44high and CD44low
cancer cell fractions as single cells in suspension indi-
cated that the CD44high subpopulation of cells forms a
markedly greater proportion of tumour spheres (Fig. 1N
and 1O), a property related to tumour initiating ability
[22,30].
Both holoclones and CD44high cell fractions of malignant 
cell lines are resistant to UVB- and drug-induced apoptosis
Following UVB irradiation, counts of cells within individ-
ual colonies of unsorted HNSCC cell lines indicated sig-
nificantly greater cell loss from paraclone colonies than
from holoclones (Fig. 2A and 2B) and higher number of
cells positive for Annexin V (Fig. 2C) and cleaved-Cas-
pase 3 in paraclones and meroclones than in holoclones.
Labelling with BrdU confirmed previous observations
[19,31] of high levels of cell proliferation in both holo-
clone and paraclone colonies (Fig. 2D and 2E), indicating
that increased survival of cells in holoclones was not sim-
ply due to proliferative quiescence. Quantitative assess-
ment of apoptosis by triple-staining with anti-CD44-PE,
Annexin V-FITC, and DAPI and FACS analysis showed
detectable (baseline) levels of apoptosis in control (un-
stimulated) cultures that significantly increased on expo-
sure to UVB, Cisplatin, NCZ, TNF or Etoposide (Fig. 2H,
2I and Table 1). In each of the HNSCC, breast and pros-
tate carcinoma cell lines, the CD44high cell fraction
showed significantly lower rates of apoptosis as com-
pared to the CD44low subset (Table 1). Stimulation for
various time lengths and concentrations of UVB, Cispla-
tin, NCZ, or Etoposide consistently induced a time- and
dose- dependent apoptosis in the general population, but
the rates of apoptosis in CD44high populations remained
proportionately lower (Fig. 2F, 2G and Table 1). The pro-
portion of CD44high cells remaining after apoptotic chal-
lenge was typically increased (Table 1), indicating the
selective survival of this fraction. More significant levels
of cell death could be observed in the CD44high fraction of
cells when the CaLH3 cells were exposed to very high
doses apoptosis-inducing drugs. However, the cell death
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Figure 1 Identification of subsets of cells with stem-like properties in cells derived from normal and malignant human epithelia. Holoclone 
(h), meroclone (m) and paraclone (p) colonies formed by CaLH3 (A) and Ca1 (D) cell lines viewed by phase contrast microscopy and after staining for 
CD44 (B and E) illustrate the small, refractile, tightly-packed holoclone cells and their strong cell surface staining for CD44. Representative FACS plots 
for CaLH3 and CA1 cell lines (C and F), two specimens of HNSCC (G, H), and normal oral keratinocytes (NOK) (I). For HNSCC and Ca1 the subpopulation 
of CD44high formed quite distinct populations, but CaLH3 and NOK showed a more continuous distribution and in this case the 3-5% of cells with the 
highest CD44 expression was arbitrarily selected as being the subpopulation of CD44high cells. Representative images of cells plated after FACS sorting 
for CD44 expression in CaLH3 and Ca1 cell lines (J and K) and early (p2) NOK cultures (L). The subpopulation of CD44high cells (left flask in each panel) 
showed greater clonogenicity than the subpopulation of CD44low cells in both normal and neoplastic-derived cells. Cell lines formed tumour spheres 
when growing in soft agar (M - representative image of MCF7 cell line), but the CD44high cell fractions formed a significantly larger proportion of 
spheres than the CD44low fraction when seeded at clonal density in soft agar (N) or when plated as single cells in culture medium in non-adherent 
plates (O).
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than in the CD44low fraction of cells (Fig. 2K), displaying
the same pattern of resistance to apoptosis-inducing
drugs even at these very high doses. DilC1(5) release due
to the loss of the mitochondrial membrane potential in
cells undergoing apoptosis was used as an alternative
method to assess cell death, and it also indicated a clear
pattern of resistance for the CD44high cell fractions to
apoptosis-inducing stimuli (Fig. 2J). Significantly higher
numbers of floating (dead) cells were found 4 days after
apoptosis-inducing treatment in the pre-sorted CD44low
cells than in the pre-sorted CD44high cells of the CA1 cell
line, indicating the increased resistance of the CD44high
fraction of cells long term after treatment as well (Fig.
2L). Sorted cells of the CA1 cell line (CD44high and
CD44low fractions) were exposed to drugs for 48 hours,
then trypsinized and plated again at clonal density.
CD44high fraction of the cells exposed to NCZ gave rise to
Figure 2 Analysis of cell death in carcinoma-derived cell lines. Representative image of holoclone and paraclone colonies of 5PT cell line before 
(A) and 24 hours after (B) UVB irradiation showing greater loss of cells from the paraclone colony (59.7 ± 8.7% cells remaining, compared to 89.3 ± 
10.7% cells remaining in holoclones, p < 0.01). Annexin V of H357 colonies showed higher numbers of apoptotic cells in paraclones (C), while BrdU 
staining showed similar proliferation rates in both holoclones and paraclones (D, E). Quantification of Annexin V in Ca1 cell line exposed to UVB (F) 
and NCZ (G) showed dose-related increases of apoptosis for CD44low cells, but markedly lower responses for CD44high cell populations. Representative 
FACS plots (H, I), showing significantly lower levels of apoptosis among CD44high cells than in CD44low cells (p < 0.01). Apoptosis in the MCF7 breast 
cell line before and after exposure to 10mj UVB and 10 ng/ml TNF assayed by staining for DilC1(5) and PI (J), showing significantly lower apoptosis in 
CD44high cells (p < 0.01). Exposure of CaLH3 cell line to very high doses of NCZ (250 ng/ml) showed similar pattern of response as obtained at lower 
doses of drugs (K). Fewer CD44high cells of Ca1 cell line were found dead (floating) 4 days after inducing of apoptosis when compared with CD44low 
cells, indicating their increased resistance long term after treatment (L). The recovery of cells after exposure to apoptosis-inducing drugs was signifi-
cantly higher in CD44high cells compared to CD44low cells of the Ca1 cell line (M, N).
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% cells in G2 in
CD44low




Ctrl 24 h 3.0 ± 0.2 1.4 ± 0.4 0.9 ± 0.1 28.7 ± 4.2 49.1 ± 4.9##
5mJ UV 24 h 4.0 ± 0.2 3.3 ± 0.1* 1.1 ± 0.1# 22.5 ± 0.9 56.0 ± 4.0##
Ctrl 48 h 3.7 ± 0.6 2.3 ± 1.0 1.0 ± 0.4# 23.6 ± 3.6 30.8 ± 1.5#
250 μM CP 48 h 3.2 ± 0.2 5.5 ± 4.8 2.2 ± 0.5* # 54.2 ± 2.2** 68.9 ± 0.4** #
20 ng/ml NCZ 48 h 9.1 ± 0.4* 4.9 ± 0.7* 1.6 ± 0.2# 27.2 ± 7.1 49.5 ± 2.8*
CaLH3
(n = 3)
Ctrl 24 h 3.1 ± 0.3 2.8 ± 1.2 1.3 ± 0.5# 36.4 ± 2.0 42.3 ± 4.1#
5mJ UV 24 h 3.1 ± 0.3 5.4 ± 0.9* 1.1 ± 0.2# 43.1 ± 2.4* 51.7 ± 0.4* #
Ctrl 48 h 3.3 ± 0.6 2.7 ± 1.4 1.9 ± 0.6# 24.4 ± 9.4 34.3 ± 5.1#
250 μM CP 48 h 4.1 ± 0.7 22.2 ± 7.8* 19.0 ± 1.8** 66.6 ± 2.8** 73.0 ± 4.1** #
20 ng/ml NCZ 48 h 6.2 ± 0.2** 8.8 ± 1.6** 2.3 ± 0.5# 18.1 ± 0.7 40.2 ± 2.4* #
5PT
(n = 3)
Ctrl 24 h 3.3 ± 0.1 1.3 ± 0.2 1.7 ± 0.4 25.6 ± 0.7 60.7 ± 5.7##
5mJ UV 24 h 4.4 ± 0.3** 5.5 ± 2.7* 2.6 ± 1.0 37.3 ± 17.0 65.9 ± 10.0#
Ctrl 48 h 3.1 ± 1.5 1.6 ± 0.5 1.0 ± 0.4# 18.7 ± 4.2 31.1 ± 1.9##
250 μM CP 48 h 3.6 ± 0.9 6.3 ± 0.9** 1.8 ± 0.8# 46.0 ± 12.0 66.1 ± 2.6**
20 ng/ml NCZ 48 h 3.4 ± 1.1 3.5 ± 0.3** 2.1 ± 0.6* # 17.1 ± 1.1 27.7 ± 2.3##
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fraction (Fig. 2M, 2N), although for the exposure to UV
this was not significantly different.
Apoptotic resistance of CD44high cells is associated with 
longer time spent in the G2 phase of cell cycle
FACS analysis after staining the cell populations for
CD44 and DNA content indicated significant cell cycle
differences between CD44high and CD44low cells (Fig. 3A
and Table 1). In un-stimulated cells, the proportion of
cells in the G2 phase of the cell cycle was consistently and
significantly higher for the CD44high subset of cells than
for the CD44low cells (Table 1), at the expense of G1 phase
of the cell cycle (Fig. 3). Treatment with NCZ or Cisplatin
induced small increases in the fraction of CD44low cells in
G2 but significant increases in the proportion of CD44high
cells (Fig. 3C). Exposure to increased concentrations of
NCZ showed that the rates of apoptosis correlated
inversely with the extent of the G2 block in the CD44high
cells (Fig. 3D). For the H357 and CaLH3 cell lines the pro-
portion of cells present in the G2 phase was also assessed
by an alternative method of quantifying the expression of
Cyclin B1, a molecule predominantly expressed in G2/M
phase. These cell lines showed a significantly greater (2-3
fold greater, p < 0.01) number of cell expressing Cyclin B1
in the CD44high cell fractions (Fig. 4A).
CD44high cells freshly isolated from HNSCC are resistant to 
drug-induced-apoptosis and spend longer in the G2 phase 
of the cell cycle
Cells freshly isolated from specimens of HNSCC were
examined immediately and at 24 and 48 h after treatment
with Cisplatin or NCZ. Negative staining for ESA was
used to exclude non-epithelial cells (i.e., fibroblasts,
inflammatory cells, etc.) from the analysis. All samples
showed a range of CD44 staining levels and some speci-
mens showed distinct sub-populations of 3-5% of cells
with high CD44 staining (Fig. 1D and 1E). The rates of
apoptosis were relatively higher for the un-treated carci-
noma cells isolated from fresh tumour biopsies then for
un-treated cultured carcinoma cell lines, but when the
CD44high and CD44low cell fractions were separately anal-
ysed, the rates of apoptosis were found to be consistently
lower for the CD44high cell fractions than for the CD44low
fractions (Fig. 3B, Table 2). This difference was statisti-
cally significant (p < 0.05) for 6 of the 8 individual tumour
specimens examined for apoptosis. FACS analysis after
staining cell populations for CD44 and DNA content
indicated significant cell cycle differences between
CD44high and CD44low un-treated cells in all tumours (Fig.
3B, Table 2), with up to a 2-fold greater number of
CD44high cells in the G2 phase of the cell cycle and lower
cell numbers in the G1 phase of the cell cycle. Treatment
with NCZ or Cisplatin (Fig. 3B) consistently increased
overall apoptotic rates, but the apoptotic rates for
CD44high cells invariably remained a couple of folds lower
than for the rest of the population. After apoptotic chal-
lenge an increased fraction of CD44low cells was also
found in G2, but consistently greater increases were
found for CD44high cells. Following apoptotic stimulation
by exposure to Cisplatin and NCZ, the size of the remain-
ing CD44high cell fractions typically increased, suggesting
again selective survival of the CD44high cells (Table 2).
CD44high cells transit the G2 compartment more slowly
The greater proportion of CD44high cells observed to be
present in G2 could result from a general increase in the
H357
(n = 3)
Ctrl 24 h 4.2 ± 1.1 2.5 ± 0.9 1.4 ± 0.4# 23.6 ± 5.9 23.3 ± 3.3
5mJ UV 24 h 3.6 ± 0.5 11.1 ± 11.6 3.6 ± 2.4# 18.3 ± 4.6 33.8 ± 15.0
Ctrl 48 h 3.3 ± 1.0 1.3 ± 0.7 1.1 ± 0.7 19.6 ± 4.5 26.9 ± 3.2#
250 μM CP 48 h 3.9 ± 0.3 8.7 ± 2.7** 2.1 ± 0.5* # 49.7 ± 1.6** 42.4 ± 1.6**
20 ng/ml NCZ 48 h 7.9 ± 2.9 5.1 ± 0.8** 2.2 ± 0.8# 15.0 ± 1.0 31.5 ± 2.00#
Table key: Data are presented as mean ± SD of 3 independent assays. * p value < 0.05 when compared with the control group; ** p value < 0.01 
when compared with the control group; # p value < 0.05 when compared with the CD44 low population from the same group; ## p value < 0.01 
when compared with the CD44 low population from the same group.
Table 1: Apoptotic and cell cycle data for human carcinoma cell lines. (Continued)
Harper et al. BMC Cancer 2010, 10:166
http://www.biomedcentral.com/1471-2407/10/166
Page 9 of 16time taken for the CD44high cells to transit G2 or from a
more permanent block of a sub-fraction of the CD44high
cell population. To assess the time taken to transit G2,
cultures of the H357 and CaLH3 cell lines were exposed
to IdU to label the cells in the S phase and the time taken
for these cells to transit through G2 and return to G1 was
then determined by sequential FACS analysis of cell
cohorts (Fig. 4B, C, D). Five hours after IdU labelling, a
higher proportion (15.6 ± 2.3% and 11.6 ± 6.2% for H357
and CaLH3 respectively) of CD44low cells (Fig. 4C) was
found to return to G1 as compared to CD44high cells (4.8
± 2.3% and 3.9 ± 2.0% respectively, p < 0.05) (Fig. 4D),
indicating that although both CD44high and CD44low cells
transit G2, CD44high cells do so more slowly. Results from
four data series for each cell line estimate the return of
CD44high cells to G1 to take 1.5 -2.0 hr longer than for
CD44low cells even in un-treated control cultures (Fig. 4E
and 4F).
Survival of CD44high cells is impaired by reducing the time 
spent in G2
Comparison of all data sets for CD44high and CD44low
cells in variously-treated individual cell lines indicated
that lower cell death was associated with larger fractions
of CD44high cells present in the G2 phase of the cell cycle
(Tabel 1 and Fig. 3D). G2-cell cycle arrest is often associ-
ated with phosphorylation of the Chk1 and Chk2 check-
point proteins and both the CD44high and CD44low cells,
and the rapid and late adhering cells of un-stimulated
populations contained low levels of phosphorylated Chk1
and Chk2 (Fig. 5A). After treatment with NCZ, their lev-
els increased but the CD44high and the rapid adhering cell
fractions showed a higher increase, suggesting greater
checkpoint activation in CD44high or rapid adhering cells
in response to DNA damage. Treatment with DBH, a
broad inhibitor of Chk1/2 checkpoint actions, resulted a
significant decrease in the percentages of CD44high cells
in the G2 phase of the cell cycle, and this reduction was
associated with significantly (p < 0.05) increased rates of
death of CD44high cells after exposure to UV (Fig. 5B).
Targeting Chk1 with siRNA significantly (p < 0.05)
decreased the fraction of CD44high cells in G2 and
increased their rate of cell death but little effect was seen
after targeting Chk2 (Fig. 5C). QPCR showed that
CD44high cell fractions or cells laser captured from holo-
clones had higher levels of transcription of Wee1 and
Myt1, the up-stream molecules involved in activation of
the G2 checkpoint response (Fig. 5D).
Apoptotic sensitivity of normal oral keratinocytes
Murine epithelial stem cells appear highly susceptible to
apoptosis [26,27] but there is little information about dif-
ferential apoptotic sensitivities of stem and amplifying
fractions of normal human oral keratinocytes (NOK). To
examine whether the greater apoptotic resistance of
malignant CD44high cells is related specifically to malig-
nant change, or is a general a property of human epithe-
lial stem cells, low passage cultures (P3-4) of NOK
isolated from normal human oral mucosa were examined
(n = 5). Analysis of the 3-5% of NOK cells with the high-
est CD44 expression showed that these cells, as for the
CD44high malignant cells, were more resistant than the
remainder of the population to apoptotic induction and
spent greater time in the G2 phase of the cell cycle (Fig.
6). Baseline levels of apoptosis increased markedly in
NOK cultures after exposure to UVB, Cisplatin, NCZ,
and Etoposide (Fig. 6 and Table 2) but the proportion of
apoptotic cells in CD44high cell fractions consistently
remained lower and the time spent in G2 became further
extended.
Discussion
The present study found that CD44high cells isolated from
fresh biopsies of HNSCC show greater resistance to drug-
induced apoptosis than cells with lower levels of CD44
expression and that this enhanced resistance is associated
with longer time spent in the G2 phase of the cell cycle.
The presence of such differences between CD44high and
CD44low cells in cell populations freshly isolated from car-
cinomas indicates their prior existence within the in vivo
tumours of origin. Similar differences between CD44high
and CD44low cells, and also between cells from holoclones
and paraclones, were also consistently found in all cell
lines investigated in the study. Cells freshly isolated from
tumours tended to show somewhat higher overall rates of
apoptosis than those for cell lines but it is unclear to what
extent this reflected intrinsic differences between carci-
noma-derived cell lines and cells freshly isolated from
carcinomas. It could be due to the adaptation of cell lines
to in vitro conditions, but it could also result from the
more extensive enzymatic dissociation needed for the
fresh tumours that may have affected the apoptotic
response or even induced some degree of apoptosis in the
isolated cells. Nevertheless, taken together, the findings
of similar patterns of apoptotic resistance of CD44high cell
fractions in fresh HNSCC cells, HNSCC cell lines, and
also for cell lines derived from breast and prostate malig-
nancies, suggest that this pattern is likely to be typical of a
wide range of carcinomas.
Enhanced susceptibility of normal epithelial stem cells
to apoptosis has been proposed to act as a defence against
malignancy by eliminating stem cells that have acquired
even minor DNA damage [31]. Normal murine epithelial
stem cells show differentially high rates of apoptosis both
in vitro and in vivo [31,32] and the development of
murine skin cancer has been associated with acquisition
of stem cell resistance to apoptosis [33]. We therefore ini-
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Figure 3 Apoptosis and cell cycle parameters for CD44low and CD44high cell populations in carcinoma-derived cell lines and fresh biopsies 
from HNSCC. Representative FACS plots analysing apoptosis (left panel) and cell cycle (right panel) in CD44low and CD44high sub-populations of H357 
cell line exposed to NCZ (A), showing that, in both control cells and cells exposed to 20 ng/ml NCZ, markedly lower levels of apoptosis and greater 
proportion of cells in the G2 phase of the cell cycle are found among CD44high cells than in the CD44low cells (for both p < 0.01). Data from cells isolated 
from fresh tumours (B) either untreated, treated with 20 ng/ml NCZ for 24 hours, or 250 μM Cisplatin for 48 hours showed a consistently higher level 
of apoptosis for CD44low cells than for CD44high cells and consistently larger fractions of CD44high cells in the G2 phase of the cell cycle and smaller 
fractions in G1 phase of the cell cycle (for both p < 0.05). After treatment with NCZ or Cisplatin the proportion of apoptotic cells in both cell fractions 
increased but remained 2-4 fold lower for CD44high cells which also showed a marked increase in the proportion of cells in G2. Graph showing the 
consistent difference in G2 block between CD44high and CD44low sub-populations of Ca1 cell line treated with increasing concentrations of NCZ (C) 
and the inverse correlation between the proportion of cells in G2 block and the proportion of Annexin V positive cells in CD44high cells at various levels 
of NCZ exposure (D).
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Figure 4 Cyclin B staining and analysis of passage through G2 by IdU pulse-chase. FACS analysis of co-staining for CD44 and cyclin B1 of CaLH3 
cell line (A): panels A1 and A2 show gates positioned to identify CD44highand cyclin B1 positive cells respectively; panels A3 and A4 show the distribu-
tion of cyclin B1 positive cells in CD44high and CD44low cell fractions respectively (p < 0.01). The same assay for the Ca1 cell line indicated 49.0 ± 3.5% 
of CD44high cells expressing cyclin B1 compared to 14.9 ± 0.2% of CD44low cells (p < 0.01). FACS plots of H357 cell line triple stained for DNA content 
with DAPI and with antibodies against CD44 and IdU adducts showing cell cycle distribution of IdU labelled cells in CD44high and CD44low cell fractions 
with time after labelling (B, C, D). Typical cell cycle distribution of total cell population at selected time points (B). Cell cycle distribution of CD44low cells 
exposed to IdU for 60 min prior to fixation (0 hours) showed cells distributed in S and early G2. By 5 hours after labelling, cells began to return to G1, 
and by 7 hours nearly 40% of cells have re-entered G1 (C). Distribution of IdU-labelled CD44high cells after initial labelling (0 hours) showed cells dis-
tributed in S and G2 as for CD44low cells. By 5 hours after labelling fewer cells have returned to G1 and by 7 hours the number was still lower (D). Data 
for all time points are summarised for H357 (E) and CaLH3 (F) cell lines.
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found for malignant CD44high cell fractions was likely to
be a result of malignant progression causing a shift of rel-
atively low apoptotic resistance of normal stem cells to
relatively high resistance of malignant stem cells. The
finding of greater apoptotic resistance of CD44high cells in
cultures of human NOK, apparently the reverse of that
for murine cells, was therefore unexpected. What effects
such differences between the apoptotic behaviours of
normal human and murine epithelial stem cells may have
on patterns of carcinogenesis remain to be determined.
However, the apoptotic resistance of CD44high cells in
early passage cultures of NOK indicates that enhanced
stem cell resistance in human malignancy is not a de novo
consequence of the malignant change but represents
enhancement of a pre-existing epithelial stem cell prop-
erty.
Various mechanisms of greater resistance of cancer
cells with stem-cell properties to apoptosis have been
previously suggested. Surprisingly, proliferative quies-
cence and presence of ABC transporters, two properties
that have often been related to therapeutic resistance of
cells with stem-like properties, did not appear to be asso-
ciated with the survival of CD44high cells in vitro. Prolifer-
ative quiescence was suggested to be radio- and chemo-
protective and appeared to protect leukemic progenitor
cells from therapeutic actions [34]. Little is known about
the in vivo proliferative rates of cells with stem-like prop-
erties in carcinomas, as compared to the bulk of the
tumour, but here we show in vitro that the CD44high cells
Table 2: Apoptotic and cell cycle data for cells derived from head and neck human oral carcinomas and from normal 
human oral mucosa.






% cells in G2 in 
CD44low




Ctrl 24 h 3.9 ± 0.4 15.1 ± 11.5 8.9 ± 8.9 12.9 ± 1.2 23.0 ± 2.2##
250 μM CP 24 h 6.8 ± 1.0* 38.5 ± 19.5 22.1 ± 16.7 15.0 ± 2.1 41.1 ± 9.7#
20 ng/ml NCZ 24 h 6.0 ± 0.8 19.9 ± 10.3 3.5 ± 2.8 11.6 ± 1.9 31.4 ± 6.0#
Ctrl 48 h 4.3 ± 0.7 14.9 ± 7.6 2.5 ± 1.6 14.1 ± 3.1 23.5 ± 5.3
20 ng/ml NCZ48 h 11.0 ± 3.9** 36.3 ± 16.3 11.0 ± 4.8 17.1 ± 2.9 76.9 ± 23.2**
NOK
(n = 5)
Ctrl 24 h 4.8 ± 1.7 5.2 ± 0.9 0.7 ± 0.4## 10.4 ± 1.9 20.9 ± 2.6#
10mJ UV 24 h 7.5 ± 2.8 7.5 ± 2.8 1.3 ± 0.5# 28.9 ± 2.1* 44.9 ± 4.7##
Ctrl 48 h 3.3 ± 0.6 15 ± 4.5 2.1 ± 0.3# 11.6 ± 1.8 16.0 ± 2.3
250 μM CP 48 h 4.6 ± 0.9 28.8 ± 4.0 3.6 ± 0.5* ## 15.8 ± 4.0 28.6 ± 2.3
Table key: Data are presented as mean ± SD of 3 independent assays. * p value < 0.05 when compared with the control group; ** p value < 0.01 
when compared with the control group; # p value < 0.05 when compared with the CD44 low population from the same group; ## p value < 0.01 
when compared with the CD44 low population from the same group.
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Page 13 of 16had greater apoptotic resistance despite their high prolif-
erative rates indicated by cell labelling and time-lapse
video (data not shown). High expression levels of ABC
transporters were also suggested to be chemo-protective
[35] and high expression levels were reported for cancer
cells with stem-like properties [21,36,37]. Apoptotic chal-
lenge with UVB was therefore initially chosen in this
study to provide a well-controlled apoptotic stimulus
unlikely to be affected by ABC status. Little difference
was subsequently detected between the responses of cells
to UVB and to several chemical agents suggesting that
differences in ABC status may not be important under
the in vitro conditions employed.
The present study showed a consistent relationship, for
all types of cells examined, between lower rates of apop-
tosis and a higher proportion of cells in G2. In line with
previous studies of glioblastomas [24,27], these data indi-
cates that the selective resistance of cells with stem-like
properties (CD44high or rapid adhering cells) to apoptosis
appears to be mediated through preferential activation of
cell cycle checkpoints in response to DNA damage, and
that these are reduced after inhibition of Chk1/Chk2
Figure 5 Analysis of components of the G2 block. Western blot of CD44high and CD44low fractions showing low baseline levels of phosphorylated 
Chk1 and Chk2 in the unstimulated Cal cell line (A). After 24 hours of exposure to 100 ng/ml NCZ levels increase, especially for CD44high cells (A). Cells 
of the Ca1 cell line before and after inhibition of Chk1/2 with DBH show increased cell death associated with partial release from the G2 block (p < 
0.01) (B). Rates of cell death and proportion of CD44high cells after independent knockdown with siRNAs of Chk1 and Chk2 in CaLH3 cells show an effect 
mainly via Chk1 (C). Message levels for Wee1 and Myt1 in CD44high and CD44low cells of the Ca1 cell line. The CD44high cells of both cell types show 
higher levels of Myt1 and CD44high Ca1 cells higher levels of Wee1 (D).
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Page 14 of 16kinases. However, it is likely that several mechanisms co-
operate to produce selective apoptotic resistance of carci-
noma cells with stem-like properties in cancers. Work on
breast cancer cell lines suggests that the radio resistance
of the CD44+/CD24- subset of cells with stem-like char-
acteristics might be related to increased activation of
Notch [28], a molecule reported to protect normal and
breast cancer cells against diverse apoptotic stimuli [38].
High levels of expression of the anti-apoptotic molecule
survivin were also reported in CD44+/CD24-/low frac-
tions of breast cancer lines [39] while high expression of
survivin was observed in the stem cell fraction of normal
keratinocytes [40], suggesting that this may be an anti-
apoptotic mechanism common to a range of epithelial
stem cells. Interestingly, several molecules shown to be
expressed at higher levels on the surface of epithelial cells
with stem-like properties, including CD44, EGFR and
ESA, are typically up-regulated in epithelial malignancies,
are associated with reduced apoptotic activity, and have
interactions that augment their individual anti-apoptotic
effects [41-43]. Determining what degrees of resistance
each mechanism typically confers, and how such mecha-
nisms may differ between individual tumours, requires
further work however.
Conclusions
The findings of this study provide support for the concept
that clinical failure to eliminate carcinomas with chemo-
and radio-therapy may be related to unique properties of
a sub-fraction of the total tumour cells that has stem-like
properties. These cells were demonstrated, by various
methods, to have a tendency to dwell longer in G2, the
phase of the cell cycle associated with DNA repair, and
release from G2 can be used to push them into apoptosis.
Differential apoptotic resistance of cells with stem-like
properties was also found in cultures of normal oral kera-
tinocytes indicating that such resistance is not a de novo
property acquired with the malignant change but a con-
stitutive feature of stem-like epithelial cells. Its presence
in freshly isolated HNSCC also indicates that it is not
simply an adaptation to in vitro conditions, suggesting
that malignant cell lines may provide an efficient and
Figure 6 Apoptosis and cell cycle parameters for sub-populations of NOK. Apoptotic rates and cell cycle parameters for CD44high and CD44low 
cell fractions of early passage normal oral keratinocytes. CD44high cells (right panel of each pair) show lower rates of apoptosis and a higher proportion 
of cells in G2 (both p < 0.05) than the CD44low sub-population (left panel of each pair) (A, B). Treatment with UVB and Cisplatin increases apoptosis (C, 
E), but the proportion of CD44high cells in apoptosis remains markedly lower (p < 0.01). UVB and NCZ treatment is also associated with increases in the 
proportion of CD44high cells in G2 and decrease in G1 phase of the cell cycle (D, F).
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Page 15 of 16effective preliminary means of studying malignant stem-
cell-like properties and may also provide systems for
analysing and devising new methods for their elimina-
tion.
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